Kansas elects a marijuana legalization supporter as governor, HHS announces funding for ibogaine research preparations, the Philippine Truth Commission releases new testimony about drug-war killings, and more.
Marijuana Policy
Kansas Governor-Elect Backs Marijuana Legalization. Cindy Holscher's victory over Republican Ty Masterson puts a legalization supporter in the governor's office, although passage still requires support in the Republican-controlled legislature, Marijuana Moment reports. Holscher has argued that Kansans already buy marijuana across state lines while Kansas loses revenue and the opportunity to regulate sales. Before the election, she said federal rescheduling could make some legislators more receptive to medical marijuana.
Virginia Study Recommends Phased Cannabis Licensing. A Cannabis Public Policy Consulting study commissioned by the Virginia Cannabis Control Authority estimates that existing demand could support 107 to 163 retail access locations, and identifies the upper end as a reasonable starting point for licensing. The report supports keeping the statutory 350-store cap while issuing licenses in phases, and presents an initial cultivation scenario with three Tier V licenses. The study estimates current annual cannabis spending by Virginia consumers aged 21 and older at $1.05 billion across all acquisition sources.
Massachusetts Advances Cannabis Testing Overhaul. The Cannabis Control Commission on November 12 advanced proposals requiring compliance testing before business-to-business as well as retail sales, more targeted microbial testing, confirmation of failed results, and labels identifying sanitized or remediated products. Commissioners also supported eliminating the Standards Laboratory license category. Draft approval is expected in December, followed by public comment beginning in January. Promulgation is tentatively planned for April 2027, with the new testing requirements taking effect six months afterward. The rules are not final.
Medical Marijuana
Senate Spending Draft Retains Medical Marijuana Protections. The Senate Appropriations Committee's November 12 fiscal 2027 Commerce, Justice, Science draft would continue the restriction on Justice Department spending to prevent listed states and territories from implementing their medical marijuana laws. Section 531 contains that protection; section 530 separately addresses industrial-hemp research. It is distinct from the veterans' research and FDA report language covered yesterday.
Nebraska Rejects Two-Year Testing Timeline but Offers No Replacement. Nebraska's Medical Cannabis Commission said November 10 that it had never established a timetable for product testing, pushing back on interpretations of an October discussion about storing harvested cannabis for up to two years. According to Zach Wendling in the Nebraska Examiner, the commission gave no new estimate. That leaves four cultivators with licenses in the state, but with unresolved testing arrangements leaving them uncertain about getting products to patients. Wendling also reports that the voter-approved law does not expressly authorize testing facilities to possess marijuana, creating a legislative obstacle.
Bedrocan Founder Says Restart Approved, Financing Still Incomplete. Bedrocan founder Tjalling Erkelens told Ben Stevens of Business of Cannabis that Dutch bankruptcy administrators and the supervising judge have approved a plan to restart the medical marijuana producer's Dutch operations under a new company, but that financing is still incomplete. The November 12 article also cites a November 9 trustees' report that listed judicial approval as pending. Separately, the Dutch government's November 6 parliamentary response says it is investigating whether UK supplies of Bedrolite can continue longer. The stakes are continuity of treatment for patients who may not be able to substitute another cannabis preparation.
See Research below for a study of medical cannabis use and opioid prescribing.
Hemp
New Jersey Signs Hemp Deadline Alignment Law. Governor Mikie Sherrill on November 12 signed S4635/A5604, a bill aligning state hemp restrictions with the federal compliance timetable. The measure extends specified exceptions for sales of intoxicating hemp beverages by eligible alcohol and cannabis licensees, and for possession or transport of intermediate hemp products during processing. The enacted measure is P.L.2026, chapter 103. The law took effect immediately; the extended exceptions run until December 11, 2026, or a later applicable federal compliance date.
Psychedelics
HHS Announces $4.9 Million for Ibogaine Development Preparations. HHS announced November 12 that ARPA-H will commit up to $4.9 million over five years toward regulatory and manufacturing groundwork for investigating ibogaine, including as a potential PTSD treatment. Cost Plus Drugs and Beond are among the named participants, and awards depend on research milestones.
HHS explicitly says the awards do not fund patient treatment or human-subject research, authorize clinical trials, or establish FDA approval. The agency acknowledges potentially life-threatening cardiac risks and says future studies will need screening, monitoring and independent oversight. Separately, NIMH has published a $20 million funding opportunity for a network studying rapid-acting psychotropic treatments, with recipients expected in summer 2027.
Clinic Leaders Describe Obstacles to Scaling Psychedelic Treatment. In original reporting published November 12, Psychedelic Alpha examines an October 15 discussion among clinic operators about delivering psychedelic therapies if they receive regulatory approval. Participants differed sharply on likely first-year patient numbers and identified reimbursement, Medicaid formularies, staffing, safety requirements and access for lower-income patients as practical constraints.
Drug Policy
Pregnancy Loss Bill Challenges Criminalization Amid Widespread Drug-Use Allegations. A bill in the US House of Representatives would seek to discourage prosecutions for pregnancy loss. Pregnancy Justice's October findings documented 902 pregnancy-related prosecutions in the first three years after Dobbs, including 871 cases involving allegations of substance use. Seventy of these cases involved pregnancy loss or neonatal death.
The Pregnancy Loss Protection Act, sponsored by Reps Joyce Beatty, Brittany Pettersen and Lauren Underwood, was introduced on November 13. According to Pregnancy Justice, it would reduce certain federal crime-control grants to states that maintain policies or practices of investigating, arresting, prosecuting or incarcerating people for pregnancy loss.
US Imposes Terrorism Designations on Three Guatemalan Groups. Matthew Lee reports for the Associated Press on new US terrorism designations announced November 13. The State Department designated Los Lorenzanas both a Foreign Terrorist Organization and a Specially Designated Global Terrorist, while Treasury designated Los Huistas and Los Mendoza Specially Designated Global Terrorists. US officials accuse the groups of financing violence through drug trafficking and maintaining ties to Mexican cartels. The designations carry sanctions consequences, while the FTO designation also creates exposure to material-support prosecutions.
Extrajudicial Killings
Philippine Truth Commission Releases Testimony on Two Killings and Funeral-Parlor Practices. In a November 13 account of its October 27 hearing, the Philippine Truth Commission describes testimony from relatives of Romeo Tuparan Jr., killed by police in July 2017, and Kiermile Ledesma, killed by unidentified gunmen in November 2016.
Tuparan's mother, Retchie Depamaylo, relayed neighbors' accounts suggesting police had mistaken him for someone else; police said he fought back and possessed a gun and shabu. Forensic pathologist Raquel Fortun examined his exhumed remains in 2022 and questioned the evidentiary basis for police blaming him for a child's gunshot injury.
In Ledesma's case, Fortun reviewed a police medical report listing nine gunshot wounds through the skull; she did not examine his body. Both mothers described funeral parlors withholding bodies until families paid large fees.
Cardinal Pablo Virgilio David described brokers receiving commissions for steering bodies to private parlors; allegations of payments to investigators remain unproven.
International
Thai Reform Advocate Warns of Retreat from Health-Based Drug Policy. In a November 13 interview and policy history, TalkingDrugs examines the gap between Thailand's stated treatment-oriented reforms, and renewed punitive proposals reported by Khaosod English on October 21. Unchisa Eaimtong discusses the consequences for people who use drugs when possession is treated as evidence of dealing and access to care remains entangled with punishment.
International System
HRI Urges UN Committee to Resume Drug-Policy Guidance. Harm Reduction International used a November 9 civil-society meeting with the UN Committee on Economic, Social and Cultural Rights to urge renewed work on its postponed General Comment on drug policy. In a statement published November 10, HRI called for attention to harm reduction in prisons, sustainable support for community-led services and barriers facing women who use drugs. It also encouraged the committee to contribute to the Commission on Narcotic Drugs' expert-panel process.
Caribbean Cultivator Leader Describes Exclusion from Legal Markets. In an interview with Ann Fordham in Health and Human Rights Journal, Junior "Spirit" Cottle, president of the Saint Vincent and the Grenadines Cannabis Revival Committee, describes economic barriers traditional growers have faced since medical legalization. Cottle says licenses and amnesty have not supplied the financing needed for compliant cultivation, leaving better-capitalized businesses in control and many traditional growers dependent on illegal markets. He calls for financial support and broader legal reform.
Research
Asian Drug Markets, Sahel Trafficking, Decriminalization, Treatment Access, Online Markets, Children's Rights, Opioid Prescribing
The Transnational Institute's November 11 report Poppies & Pills in the Golden Triangle examines changes in drug markets and community livelihoods through research involving 177 respondents in Myanmar, Thailand, southern China and northeast India. The report recommends judging policy by health, rights and livelihoods, expanding voluntary harm reduction responsive to stimulant and multiple-drug use, and supporting community participation alongside land and labor protections.
The Global Initiative Against Transnational Organized Crime's The Business of War examines illicit economies and conflict in the Sahel. Its drug-market analysis describes cocaine routes shaped by protection arrangements involving armed actors, including taxation of shipments. Field-source accounts also suggest a transport role for Islamic State Sahel along part of the route through northern Mali. The report also examines armed groups' involvement in kidnapping, gold mining and other licit and illicit economies.
A new International Journal of Drug Policy paper on realistic objectives for decriminalization draws on 16 interviews with experts and other stakeholders, including people with lived experience, law enforcement representatives and policymakers, conducted in November and December 2021, before British Columbia's pilot began. Participants identified reduced criminal-justice contact, fewer seizures of drugs held for personal use and reduced stigma as plausible primary objectives. The authors argue against judging decriminalization alone by measurable reductions in overdose deaths, which depend on other policies and services.
Another study published in IJDP, Opioid Agonist Therapy in and Beyond the COVID-19 Pandemic, analyzes 88 policy documents and identifies 300 changes across Canadian jurisdictions. Federal exemptions enabled more flexible prescribing and delivery, but provinces translated them differently. Take-home doses and monitoring requirements showed especially substantial variation. The authors warn that uneven implementation can perpetuate geographic inequities.
In a study of Snapchat's drug-seller recommendations published in IJDP, Kristoffer Aagesen tested whether deleting contacts stopped the app from suggesting drug sellers as new connections. He used 40 research accounts to enter nicotine and digital sex-work networks, then accepted drug sellers suggested by Snapchat. Over four days, 30 accounts received and accepted such suggestions; ten did not. He then deleted every contact from all 40 accounts and waited 48 hours. Snapchat still suggested drug sellers to 21 of the 30 previously connected accounts (70%). The study suggests that deleting contacts alone may not remove the platform's links to drug-selling networks.
A Health and Human Rights Journal analysis of children's place in global drug policy examines Commission on Narcotic Drugs resolutions from 2000 through 2026. The authors identify 19 child-focused resolutions among roughly 300, with only six going beyond prevention. They argue for greater attention to children's rights across drug-policy decisions, rather than treating children chiefly as a rationale for prohibition.
An observational study in the Journal of Addiction Medicine of medical cannabis use and opioid prescribing followed 8,358 chronic pain patients for 90 days and compared sustained medical cannabis use (more than 30 days) with brief use (30 days or less). Opioid-prescription discontinuation, defined as a gap of at least 45 days, was recorded in 15.5% of the sustained-use group versus 7.6% of the brief-use group. The comparison was not with cannabis-naive patients, and residual confounding prevents a causal conclusion. The study did not measure pain relief or overdose outcomes and found no significant association among patients starting at 90 or more morphine-milligram equivalents per day.
Events
The International Society for the Study of Drug Policy (ISSDP) and Kyoto University’s Center for Southeast Asian Studies are co-organizing From Opium Trade to Drug Control on November 16, online via Zoom and in Kyoto, from 1:30-4:00am Eastern (3:30-6:00pm Japan time). Shohei Okubo will discuss opium and Dutch colonial governance in maritime Asia, and Chika Yamada will examine the emergence of drugs as a security issue in Indonesia. Gideon Lasco will serve as discussant.
UNODC will hold an online civil-society briefing on drug policy on November 16, 9:00-10:30am Eastern (3:00-4:30pm Vienna time). Topics include decriminalization, harm reduction, access to controlled medicines, alternative development and synthetic drugs.
The online Psychedelic Lived Experiences Summit, November 20–22, will bring patients, families, clinicians and researchers together to discuss safety, outcomes and gaps in support after psychedelic treatment.
The International Society for the Study of Drug Policy is accepting conference abstracts through December 22. Its June 22–26, 2027 conference at Universidad EAFIT in Medellín, Colombia, will address drug policy, health and justice; submissions are accepted in English and Spanish.
The Florida Harm Reduction Conference takes place January 18–21, 2027 at the Hilton St. Petersburg Bayfront. Sessions will address syringe services, overdose prevention, infectious diseases and barriers to care. Early-bird ticket prices run through November 30.
This work by StoptheDrugWar.org is licensed under Creative Commons Attribution-ShareAlike 4.0 International
Add new comment